General
Preferred name
CILAZAPRIL
Synonyms
Ro 31-2848 ()
Cilazapril Monohydrate ()
Cilazapril (monohydrate) ()
Ro 31-2848 monohydrate ()
Cilazaprilum ()
Inhibace ()
Initiss ()
Cilazapril anhydrous ()
Justor ()
RO 31-2848/006 ()
RO-312848006 ()
Cilazapril hydrate ()
Vascace ()
Anhydrous cilazapril ()
P&D ID
PD009546
CAS
92077-78-6
88768-40-5
Tags
available
drug
prodrug
Drug indication
Cardiovascular disease
Congestive heart failure
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.;Target: ACE;Cilazapril is a new nonthiol group containing angiotensin converting enzyme (ACE) inhibitor. Cilazapril has been investigated in more than 4000 patients with all degrees of hypertension, as well as in the special patient groups such as the elderly, renally impaired, and patients with concomitant diseases, such as congestive cardiac failure or chronic obstructive pulmonary disease [1]. Cilazapril is a very potent and highly effective converting enzyme inhibitor. Doses well below 5 mg/day will probably suffice for therapeutic efficacy [2].
DESCRIPTION Cilazapril is a prodrug. It is metabolically converted to the drug cilazaprilat. Cilazapril does not appear to have marketing approval for human use in the US or EU, although national approval agencies may have granted marketing authorisation. (GtoPdb)
ABSORPTION Maximum plasma concentrations of cilazaprilat are reached within two hours after; administration of cilazapril.
DESCRIPTION Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure. (BOC Sciences Bioactive Compounds)
Compound Sets
15
BOC Sciences Bioactive Compounds
cilazapril-monohydrate-cas-92077-78-6-item-84-155760
Cayman Chemical Bioactives
29777
ChEMBL Approved Drugs
CHEMBL515606
ChEMBL Drugs
CHEMBL515606
Drug Repurposing Hub
DrugBank
DB01340
DrugBank Approved Drugs
DB01340
DrugCentral
641
DrugCentral Approved Drugs
641
DrugMAP
DM4V6JA
DrugMAP Approved Drugs
DM4V6JA
Guide to Pharmacology
6459
MedChem Express Bioactive Compound Library
HY-A0043A
NPC Screening Collection
ReFrame library
External IDs
53
Properties
(calculated by RDKit )
Molecular Weight
417.23
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
1
cLogP
1.6
TPSA
99.18
Fraction CSP3
0.59
Chiral centers
3.0
Largest ring
7.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Angiotensin-converting Enzyme (ACE)
ACE
Pathway
Metabolic Enzyme/Protease
Indication
hypertension, congestive heart failure
MOA
angiotensin converting enzyme inhibitor
Therapeutic Class
Antihypertensive Agents
Source data